<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00848302</url>
  </required_header>
  <id_info>
    <org_study_id>K23HLOBO247</org_study_id>
    <secondary_id>K23HLOBO247</secondary_id>
    <nct_id>NCT00848302</nct_id>
  </id_info>
  <brief_title>Endothelial Function in Human Arteries</brief_title>
  <official_title>Endothelial Function in Human Arteries</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Up to 30 patients with lower extremity disease scheduled to undergo diagnostic angiography&#xD;
      will undergo baseline bloodwork and IVUS (intravascular ultrasound), followed by dosing with&#xD;
      L-arginine to assess changes in endothelial function.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We will assess doses of regional L-arginine supplementation in patients undergoing elective&#xD;
      angiography for lower extremity PAD. Assessment of EDR and EIR with IVUS in patent arteries&#xD;
      will be performed with one of 3 doses of catheter-directed L-arginine. We will obtain plasma&#xD;
      samples from the peripheral arteries and assay amino acid levels and protein oxidation&#xD;
      products using mass spectrometry. These experiments will determine the optimal L-arginine&#xD;
      supplementation dose to be used in further studies. We expect to show that L-arginine&#xD;
      supplementation will have a more significant effect on vessels less affected by&#xD;
      atherosclerosis, but that this effect diminishes with greater atheroma accumulation as&#xD;
      measured by IVUS virtual histology. Also, we expect L-arginine supplementation to be most&#xD;
      effective in vessels with low baseline L-arginine levels. Lastly, we will compare local&#xD;
      arterial factors obtained via catheter-directed arterial sampling (NOx, L-arginine,&#xD;
      nitrotyrosine levels) to traditional serum risk factors (glucose, HbA1c, LDL, homocysteine&#xD;
      and hs C-reactive protein).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>IVUS mediated assessment of endothelial-dependent (EDR) and endothelial-independent (EIR) vasorelaxation before and after catheter-directed L-arginine delivery in patent arteries.</measure>
    <time_frame>Procedural</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Local arterial factors including peripheral L-arginine and nitrotyrosine levels via mass spectrometry and morphologic parameters of plaque composition.</measure>
    <time_frame>Procedural</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Endothelial Dysfunction</condition>
  <arm_group>
    <arm_group_label>L-arginine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Assess the effects of regional L-arginine supplementation in patients with chronic lower extremity occlusive disease undergoing angiography</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-arginine</intervention_name>
    <description>30 patients will receive either 50, 100 or 500mg L-arginine supplementation infused via a end-hole catheter</description>
    <arm_group_label>L-arginine</arm_group_label>
    <other_name>Nitric oxide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age &gt;18 years&#xD;
&#xD;
          -  symptoms of intermittent claudication, rest pain or minor tissue loss (Rutherford&#xD;
             Category I-V)&#xD;
&#xD;
          -  ABI of &lt;.90&#xD;
&#xD;
          -  angiographic demonstration of a 100mm patent segment of superficial femoral artery&#xD;
             containing at least one distal runoff vessel&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  acute limb ischemia,&#xD;
&#xD;
          -  contraindication to angiography (creatinine &gt;2.5)&#xD;
&#xD;
          -  concurrent oral anticoagulant therapy that cannot be safely withheld&#xD;
&#xD;
          -  extensive tissue loss or gangrene&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vikram Kashyap, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cleveland Clinic Vascular Surgery</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>February 12, 2009</study_first_submitted>
  <study_first_submitted_qc>February 19, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2009</study_first_posted>
  <last_update_submitted>March 6, 2017</last_update_submitted>
  <last_update_submitted_qc>March 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>peripheral vascular disease</keyword>
  <keyword>endothelial dysfunction</keyword>
  <keyword>intravascular ultrasound</keyword>
  <keyword>L-Arginine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitric Oxide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

